56 results
Page 2 of 3
8-K
EX-99.1
k6c yzq140nmyycc
9 Nov 21
3 of 5 (60%) patients achieved a partial response All 5 patients treated demonstrated tumor decrease from baseline
8:29am
8-K
EX-99.1
tape bp5zg8w3
28 Oct 21
Aravive Reports Third Quarter 2021 Financial Results and Provides Corporate Updates
4:06pm
8-K
EX-99.1
fz37zi4hs si163nz6
9 Aug 21
Aravive Announces First Patient Dosed in Phase 1b/2 Clinical Trial of AVB-500 for the Treatment of Pancreatic Adenocarcinoma
7:09am
8-K
EX-99.1
zmxnd
5 Aug 21
Aravive Reports Second Quarter 2021 Financial Results and Provides Corporate Updates
7:06am
8-K
EX-99.1
ewdnekj3
15 Jul 21
Aravive Achieves Second Development Milestone from 3D Medicines
7:05am
8-K
EX-99.1
8vm3z
24 Jun 21
Regulation FD Disclosure
7:07am
8-K
EX-99.1
fwgfr78zl3 tp8
18 May 21
Aravive Announces Three New Appointments to its Board of Directors
7:05am
8-K
EX-99.2
ppi27
6 May 21
Aravive continues to expand development of AVB-500 in multiple indications and combination treatments with first-line treatment for pancreatic cancer
7:08am
8-K
EX-99.1
r7gu9
6 May 21
Aravive continues to expand development of AVB-500 in multiple indications and combination treatments with first-line treatment for pancreatic cancer
7:08am
8-K
EX-99.1
pgh9o
27 Apr 21
Aravive Announces First Patient Dosed in Phase 3 Registrational Trial Evaluating AVB-500 in Patients with Platinum Resistant Ovarian Cancer
7:10am
8-K
EX-99.2
p7630 8wtf5l
27 Apr 21
Aravive Announces First Patient Dosed in Phase 3 Registrational Trial Evaluating AVB-500 in Patients with Platinum Resistant Ovarian Cancer
7:10am
8-K
EX-99.1
3onwg5oz62rw7lg
16 Mar 21
Aravive Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Updates
7:15am
8-K
EX-99.1
zh3a84xwv96d
8 Mar 21
Aravive Announces First Patient Dosed in Phase 1b/2 Clinical Trial of AVB-500 in Patients with Clear Cell Renal Cell Carcinoma
7:05am
8-K
EX-99.1
81x 24eqn
2 Mar 21
Regulation FD Disclosure
8:00am
424B5
83dtmxxn
16 Feb 21
Prospectus supplement for primary offering
7:05am